Soleus Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Soleus Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-78,000	Closed	-$2.04M	–	102
2022 Q4	$2.04M	Hold	78,000	–	–	0.29%	59
2022 Q3	$1.53M	Sell	78,000 -10,000	-11%	-$201K	0.21%	61
2022 Q2	$1.54M	Buy	+88,000	New	+$1.38M	0.24%	63
2022 Q1	–	Sell	-298,700	Closed	-$4.87M	–	82
2021 Q4	$4.87M	Buy	+298,700	New	+$4.25M	0.49%	39
2020 Q2	–	Sell	-16,240	Closed	-$222K	–	73
2020 Q1	$222K	Buy	+16,240	New	+$192K	0.26%	43

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Soleus Capital Management's KDNY Position: Q1 2023 in Review

Soleus Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 78,000 shares — an estimated $2.04M sold.

Soleus Capital Management first reported a position in KDNY in Q1 2020 and held it in 5 quarters. The position peaked at $4.87M in Q4 2021. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

Soleus Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Soleus Capital Management sold 78,000 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $2.04M.
Soleus Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Soleus Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $4.87M in Q4 2021.
157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Soleus Capital Management's 13F filing for Q1 2023, filed 15 May 2023.